Tagged with GSK,

China Pharma News: Paxlovid’s Exclusion from National Insurance; CanSino’s mRNA Booster Trial; WuXi/GSK T-cell Deal; Biocytogen/Hansoh Antibody Collab
PharmaBoardroom’s 10 Most Read Interviews of 2022
LatAm’s Potential as a Clinical Trials Hub
Access to Medicines Index 2022: Big Pharma Steps Up Access Efforts with GSK Top Again
Andre Vivan da Silva – Country Manager, GSK Brazil
Most Powerful Women in Pharma 2022
Mohamed Ali Abd El Azim – Site Director, Cairo, Primary & Small Molecules (PSM), GSK
Luis Arosemena – SVP Emerging Markets, GSK
Pharma’s Digital Journey:  Still a Way to Go
New GSK flu vaccine deal, Amylyx Pharmaceuticals’ ALS approval and Chimerix and Bavarian Nordic smallpox contracts
What’s Next for GSK after Letting Go of Consumer Healthcare?
Big Pharma’s Ukraine Response: Humanitarian Aid & Differing Russia Approaches
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here